# OnCo record nct02029443 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02029443/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02029443", "NCT02029443" ;
  schema:name "ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia"@en ;
  schema:description "A phase 1/2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02029443/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02029443> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2014-01-30" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/richter-transformation-cll/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/acalabrutinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .